Skip to content

Botulinum Toxin Brands

Botulinum toxin brands identify specific medicines, each with its own active ingredient, company relationships, and regional product information. A manufacturer, brand owner, and local commercial partner can be different companies. Product names and approved uses may also differ by country (AbbVie product information 🔗).

The directory covers products with dedicated entries in Botulinum Toxin Index. Inclusion does not establish approval or availability in a particular country. Ingredient names retain regional suffixes where applicable; the suffix is part of the name, not a separate toxin type.

Brand / product familyActive ingredientToxin typeCompany roles and primary reference
BoeyTrenibotulinumtoxinEEAbbVie Limited is the EU authorisation holder; AbbVie / Allergan is the related company group (Boey — EMA 🔗).
Botox / Botox CosmeticOnabotulinumtoxinAAAllergan, part of AbbVie; Botox Cosmetic belongs to Allergan Aesthetics (Botox Cosmetic — DailyMed 🔗).
DaxxifyDaxibotulinumtoxinA-lanmARevance is the company named in the U.S. manufacturing statement (Daxxify — DailyMed 🔗).
DysportAbobotulinumtoxinAAIpsen Biopharm manufactures it; Galderma holds aesthetic commercial rights in licensed territories (Dysport — DailyMed 🔗; Galderma brands 🔗).
HengliBotulinum toxin type AALanzhou Biotechnique Development is the production unit; Lanzhou Institute provides the historical development context (Sinopharm biological products 🔗; Fosun Pharma brand record 🔗).
Jeuveau / NabotaPrabotulinumtoxinA; prabotulinumtoxinA-xvfs in the U.S.ADaewoong Pharmaceutical manufactures the product; Evolus commercializes Jeuveau in the U.S. (Jeuveau — DailyMed 🔗).
LetyboLetibotulinumtoxinA; letibotulinumtoxinA-wlbg in the U.S.AHugel is the manufacturer identified in U.S. product information (Letybo — DailyMed 🔗).
Myobloc / NeuroblocRimabotulinumtoxinBBSolstice Neurosciences is named in U.S. manufacturing information; Supernus includes Myobloc in its commercial portfolio (Myobloc — DailyMed 🔗; Supernus products 🔗).
Re N ToxBotulinum toxin type AAPharmaResearchBio manufactures the product (PharmaResearch company announcement 🔗).
RelfydessRelabotulinumtoxinAAGalderma developed and manufactures the product (Galderma brands 🔗).
XeominIncobotulinumtoxinAAMerz Pharmaceuticals GmbH is the manufacturer identified in U.S. product information (Xeomin — DailyMed 🔗).

Company roles apply to the product and market described by the cited record. The company directory provides broader ownership, development, manufacturing, and commercial relationships.

Vistabel and Vistabex are European aesthetic names within the Botox product family. The Spanish Vistabel leaflet lists Vistabel in numerous EEA countries and Vistabex in Italy. These regional names retain national product information; they do not create one worldwide approval profile (Vistabel patient leaflet — AEMPS 🔗).

A product family can have several regional names without having one worldwide label. The Jeuveau / Nabota entry connects Daewoong’s product with Jeuveau and Nuceiva; EMA records Nuceiva under Evolus Pharma B.V. (Nuceiva — EMA 🔗). The local authorisation holder and approved product information remain market-specific.

Myobloc / Neurobloc illustrates why regional names also need historical context: NeuroBloc’s EU authorisation was withdrawn, so its familiar name does not establish present EU availability (NeuroBloc — EMA 🔗).

Hengli connects the China-market name with Prosigne in Brazil and Lantox in historical literature. The Brazilian Prosigne label names Cristália as local registration holder and importer; that role does not establish a Chinese approval-holder relationship. (Prosigne patient information — Cristália 🔗)

Type A, B, and E identify different toxin types, also called serotypes. Products sharing type A still have distinct preparations and potency assays. The Botox Cosmetic prescribing information states that its units cannot be compared with or converted into those of another botulinum toxin product (Botox Cosmetic — DailyMed 🔗).

Type A vs type B and type E explain the biological distinctions. Unit interpretation explains why a larger unit count does not establish a stronger product. Neither a shared toxin type nor a shared company establishes interchangeable units or clinical superiority.

ReferenceMain question
U.S. FDA regulatory statusWhich products are approved, and which applications remain at other regulatory stages?
U.S. FDA indication matrixWhich uses and patient limits appear in each U.S. label?
EU approval overviewHow do centralised and national authorisations work, and where is approved product information recorded?
Japan approval contextHow are Japanese approval records distinguished from overseas or imported brand names?

For historical dates, the U.S. FDA approval timeline records original approvals and selected indication expansions. Current approved uses remain defined by the applicable product information, rather than by a brand directory or an approval date.

1. Which distinction explains Dysport's company relationships?
2. What does a shared type A classification establish about two brands?
3. Which reference answers whether a use is included in a product's U.S. label?